News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Experts urge early detection & better access to care
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Subscribe To Our Newsletter & Stay Updated
